{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.05","upperLimit":"11.27","value":"8.57"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"270"}],"units":"Participants"}],"title":"All treated participants"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.37","upperLimit":"8.08","value":"5.95"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"}],"units":"Participants"}],"title":"PD-L1 <1%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.10","upperLimit":"19.12","value":"11.86"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"}],"units":"Participants"}],"title":"PD-L1 >= 1%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.96","upperLimit":"9.00","value":"6.24"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"187"}],"units":"Participants"}],"title":"PD-L1 <5%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.63","upperLimit":"22.14","value":"13.54"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"}],"units":"Participants"}],"title":"PD-L1 >=5%"}],"denoms":[{"counts":[{"groupId":"OG000","value":"270"}],"units":"Participants"}],"description":"Overall Survival was defined as the time from first dosing date to the date of death. A participant who had not died was censored at last known date alive. PD-L1 expression level = membranous staining in greater than or equal to 5% and greater than or equal to 1% tumor cells.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg was administered as a 60 minute IV infusion Q2W","id":"OG000","title":"Nivolumab 3 mg/kg"}],"paramType":"MEDIAN","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From first dosing date to the date of death (up to approximately 23 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}